Prognostic Associations of Activated Mitogen-Activated Protein Kinase and Akt Pathways in Glioblastoma

Purpose: Activation of mitogen-activated protein kinase (MAPK) and members of the Akt pathway have been shown to promote cell proliferation, survival, and resistance to radiation. This study was conducted to determine whether any of these markers are associated with survival time and response to radiation in glioblastoma. Experimental Design: The expression of phosphorylated (p-)Akt, mammalian target of rapamycin (p-mTOR), p-p70S6K, and p-MAPK were assessed by immunohistochemical staining in 268 cases of newly diagnosed glioblastoma. YKL-40, a prognostic marker previously examined in these tumors, was also included in the analysis. Expression data were tested for correlations with response to radiation therapy in 131 subtotally resected cases and overall survival (in all cases). Results were validated in an analysis of 60 patients enrolled in clinical trials at a second institution. Results: Elevated p-MAPK expression was most strongly associated with poor response to radiotherapy, a finding corroborated in the validation cohort. For survival, higher expressions of p-mTOR, p-p70S6K, and p-MAPK were associated with worse outcome (all P < 0.03). YKL-40 expression was associated with the expressions of p-MAPK, p-mTOR, and p-p70S6K (all P < 0.02), with a trend toward association with p-Akt expression (P = 0.095). When known clinical variables were added to a multivariate analysis, only age, Karnofsky performance score, and p-MAPK expression emerged as independent prognostic factors. Conclusions: p-MAPK and activated members of the Akt pathway are markers of outcome in glioblastoma. Elevated expression of p-MAPK is associated with increased radiation resistance and represents an independent prognostic factor in these tumors.

[1]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[2]  M. Prados,et al.  Radiation response and survival time in patients with glioblastoma multiforme. , 1996, Journal of neurosurgery.

[3]  A. Pawson,et al.  Proliferation of human malignant astrocytomas is dependent on Ras activation , 1997, Oncogene.

[4]  W. Curran,et al.  Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. , 1998, International journal of radiation oncology, biology, physics.

[5]  P. Forsyth,et al.  Long-term Glioblastoma Multiforme Survivors: a Population-based Study , 1998, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[6]  M. Prados,et al.  Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. , 1998, International journal of radiation oncology, biology, physics.

[7]  M. Sant,et al.  Survival rates for primary malignant brain tumours in Europe. EUROCARE Working Group. , 1998, European journal of cancer.

[8]  F. Lang,et al.  Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment. , 1999, Cancer research.

[9]  S. Altschul,et al.  A public database for gene expression in human cancers. , 1999, Cancer research.

[10]  D. Vordermark,et al.  Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. , 2000, Anticancer research.

[11]  P. Dent,et al.  Inhibition of the mitogen activated protein kinase pathway potentiates radiation-induced cell killing via cell cycle arrest at the G2/M transition and independently of increased signaling by the JNK/c-Jun pathway. , 2000, International journal of oncology.

[12]  Susan M. Chang,et al.  Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. , 2001, International journal of radiation oncology, biology, physics.

[13]  M. Berger,et al.  EGFR overexpression and radiation response in glioblastoma multiforme. , 2001, International journal of radiation oncology, biology, physics.

[14]  Keiji Suzuki,et al.  Extremely low-dose ionizing radiation causes activation of mitogen-activated protein kinase pathway and enhances proliferation of normal human diploid cells. , 2001, Cancer research.

[15]  Susan M. Chang,et al.  Glioblastoma Patients Epidermal Growth Factor Receptor , and Survival in Analysis of Complex Relationships between Age , p 53 , Updated , 2001 .

[16]  S. Gullans,et al.  Differential gene expression profiling in human brain tumors. , 2001, Physiological genomics.

[17]  R. Muschel,et al.  The Ras radiation resistance pathway. , 2001, Cancer research.

[18]  C. Gondi,et al.  Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro , 2002, Oncogene.

[19]  M Hareyama,et al.  MEK/ERK pathway protects ionizing radiation-induced loss of mitochondrial membrane potential and cell death in lymphocytic leukemia cells , 2002, Cell Death and Differentiation.

[20]  James R. Van Brocklyn,et al.  Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: role of ERK MAP kinase and phosphatidylinositol 3-kinase β , 2002 .

[21]  Mark R Gilbert,et al.  Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. , 2002, Cancer research.

[22]  C. Rhee,et al.  Modulation of phorbol ester-induced regulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases by SB203580, a specific inhibitor of p38 mitogen-activated protein kinase. , 2002, Journal of neurosurgery.

[23]  H. Ling,et al.  The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. , 2002, The Biochemical journal.

[24]  H. Rodemann,et al.  Early growth response-1 gene (Egr-1) promoter induction by ionizing radiation in U87 malignant glioma cells in vitro. , 2002, European journal of biochemistry.

[25]  Brett L Carlson,et al.  Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. , 2002, Cancer research.

[26]  N. Socci,et al.  Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. , 2003, Molecular cell.

[27]  Alfonso Bellacosa,et al.  The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. , 2003, Cancer research.

[28]  V. Kavsan,et al.  HC gp-39 gene is upregulated in glioblastomas. , 2003, Cancer letters.

[29]  Siegfried Kropf,et al.  Prognostic relevance of MAPK expression in glioblastoma multiforme. , 2003, International journal of oncology.

[30]  Paul S Mischel,et al.  Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. , 2003, Cancer research.

[31]  E. Shaw,et al.  Reexamining the radiation therapy oncology group (RTOG) recursive partitioning analysis (RPA) for glioblastoma multiforme (GBM) patients , 2003 .

[32]  S. Pinder,et al.  The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome , 2004, The Journal of pathology.

[33]  T. Nonaka,et al.  Selective inhibition of survival signal transduction pathways enhanced radiosensitivity in human esophageal cancer cell lines in vitro. , 2004, Anticancer research.

[34]  Alona Muzikansky,et al.  The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Soh,et al.  PKC-η mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways , 2004, Oncogene.

[36]  V. A. Flørenes,et al.  Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. , 2005, American journal of clinical pathology.

[37]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  K. Aldape,et al.  YKL-40 Expression is Associated with Poorer Response to Radiation and Shorter Overall Survival in Glioblastoma , 2005, Clinical Cancer Research.

[39]  K. Aldape,et al.  Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. , 2005, Cancer research.

[40]  M. Berger,et al.  Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.